Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
67
LNSR Quote, Financials, Valuation and Earnings
Last price:
$12.03
Seasonality move
:
18.65%
Day range:
$12.01 - $12.13
52-week range:
$7.25 - $17.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.41x
P/B ratio:
33.92x
Volume:
20.9K
Avg. volume:
52.6K
1-year change:
38.2%
Market cap:
$143.5M
Revenue:
$53.5M
EPS (TTM):
-$4.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LNSR
LENSAR, Inc.
|
$17.8M | -$0.08 | 30.98% | -90.51% | $15.00 |
|
ADGM
Adagio Medical Holdings, Inc.
|
-- | -$0.24 | -100% | -91.79% | $4.00 |
|
INBS
Intelligent Bio Solutions, Inc.
|
$1.4M | -- | 160.36% | -- | -- |
|
LAB
Standard BioTools, Inc.
|
$18M | -$0.02 | -60.4% | -72.53% | $1.65 |
|
MOVE
Movano, Inc.
|
$3.4M | -$7.10 | 76.06% | -41.21% | $30.00 |
|
NPCE
NeuroPace, Inc.
|
$24.6M | -$0.19 | 13.69% | -5.76% | $19.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LNSR
LENSAR, Inc.
|
$12.01 | $15.00 | $143.5M | -- | $0.00 | 0% | 2.41x |
|
ADGM
Adagio Medical Holdings, Inc.
|
$1.06 | $4.00 | $22.3M | 218.00x | $0.00 | 0% | 118.08x |
|
INBS
Intelligent Bio Solutions, Inc.
|
$4.98 | -- | $4.8M | -- | $0.00 | 0% | 9.90x |
|
LAB
Standard BioTools, Inc.
|
$1.47 | $1.65 | $565.3M | -- | $0.00 | 0% | 4.32x |
|
MOVE
Movano, Inc.
|
$7.97 | $30.00 | $6.7M | -- | $0.00 | 0% | 12.06x |
|
NPCE
NeuroPace, Inc.
|
$16.19 | $19.25 | $539.3M | -- | $0.00 | 0% | 5.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LNSR
LENSAR, Inc.
|
-31.16% | -1.208 | 1.79% | 0.65x |
|
ADGM
Adagio Medical Holdings, Inc.
|
106.35% | 2.155 | 73.62% | 0.48x |
|
INBS
Intelligent Bio Solutions, Inc.
|
35.02% | 2.804 | 21.48% | 0.47x |
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.589 | 5.49% | 1.93x |
|
MOVE
Movano, Inc.
|
212.35% | 2.628 | 67.05% | 0.29x |
|
NPCE
NeuroPace, Inc.
|
79.36% | 0.212 | 20.74% | 3.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LNSR
LENSAR, Inc.
|
$5.8M | -$7.6M | -684.94% | -1013.45% | -52.95% | -$3.5M |
|
ADGM
Adagio Medical Holdings, Inc.
|
-$531K | -$5.7M | -193.23% | -340.49% | -- | -$3.5M |
|
INBS
Intelligent Bio Solutions, Inc.
|
$214.9K | -$2.9M | -213.68% | -255.54% | -263.64% | -$2.9M |
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
MOVE
Movano, Inc.
|
-$200K | -$2.6M | -337.24% | -410.28% | -3238.75% | -$1.6M |
|
NPCE
NeuroPace, Inc.
|
$21.2M | -$2.6M | -27.09% | -149.8% | -9.51% | -$2M |
LENSAR, Inc. vs. Competitors
-
Which has Higher Returns LNSR or ADGM?
Adagio Medical Holdings, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of --. LENSAR, Inc.'s return on equity of -1013.45% beat Adagio Medical Holdings, Inc.'s return on equity of -340.49%.
Company Gross Margin Earnings Per Share Invested Capital LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M ADGMAdagio Medical Holdings, Inc.-- -$0.66 $20.7M -
What do Analysts Say About LNSR or ADGM?
LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 24.9%. On the other hand Adagio Medical Holdings, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 300%. Given that Adagio Medical Holdings, Inc. has higher upside potential than LENSAR, Inc., analysts believe Adagio Medical Holdings, Inc. is more attractive than LENSAR, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNSRLENSAR, Inc.0 2 0 ADGMAdagio Medical Holdings, Inc.1 0 0 -
Is LNSR or ADGM More Risky?
LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Adagio Medical Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LNSR or ADGM?
LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Adagio Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNSR or ADGM?
LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Adagio Medical Holdings, Inc. quarterly revenues of --. LENSAR, Inc.'s net income of -$3.7M is higher than Adagio Medical Holdings, Inc.'s net income of -$10.1M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Adagio Medical Holdings, Inc.'s PE ratio is 218.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.41x versus 118.08x for Adagio Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M ADGMAdagio Medical Holdings, Inc.118.08x 218.00x -- -$10.1M
-
Which has Higher Returns LNSR or INBS?
Intelligent Bio Solutions, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -269.38%. LENSAR, Inc.'s return on equity of -1013.45% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.
Company Gross Margin Earnings Per Share Invested Capital LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M -
What do Analysts Say About LNSR or INBS?
LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 24.9%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 2309.64%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than LENSAR, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than LENSAR, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNSRLENSAR, Inc.0 2 0 INBSIntelligent Bio Solutions, Inc.0 0 0 -
Is LNSR or INBS More Risky?
LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LNSR or INBS?
LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNSR or INBS?
LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. LENSAR, Inc.'s net income of -$3.7M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.41x versus 9.90x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M INBSIntelligent Bio Solutions, Inc.9.90x -- $1.1M -$3M
-
Which has Higher Returns LNSR or LAB?
Standard BioTools, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -162.05%. LENSAR, Inc.'s return on equity of -1013.45% beat Standard BioTools, Inc.'s return on equity of -24.44%.
Company Gross Margin Earnings Per Share Invested Capital LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M LABStandard BioTools, Inc.48.51% -$0.09 $427M -
What do Analysts Say About LNSR or LAB?
LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 24.9%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could grow by 5.44%. Given that LENSAR, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe LENSAR, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNSRLENSAR, Inc.0 2 0 LABStandard BioTools, Inc.1 2 0 -
Is LNSR or LAB More Risky?
LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.
-
Which is a Better Dividend Stock LNSR or LAB?
LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNSR or LAB?
LENSAR, Inc. quarterly revenues are $14.3M, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. LENSAR, Inc.'s net income of -$3.7M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.41x versus 4.32x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M LABStandard BioTools, Inc.4.32x -- $19.6M -$31.7M
-
Which has Higher Returns LNSR or MOVE?
Movano, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -5036.25%. LENSAR, Inc.'s return on equity of -1013.45% beat Movano, Inc.'s return on equity of -410.28%.
Company Gross Margin Earnings Per Share Invested Capital LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M MOVEMovano, Inc.-250% -$4.73 $1.5M -
What do Analysts Say About LNSR or MOVE?
LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 24.9%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 3664.12%. Given that Movano, Inc. has higher upside potential than LENSAR, Inc., analysts believe Movano, Inc. is more attractive than LENSAR, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNSRLENSAR, Inc.0 2 0 MOVEMovano, Inc.0 0 0 -
Is LNSR or MOVE More Risky?
LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LNSR or MOVE?
LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNSR or MOVE?
LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Movano, Inc. quarterly revenues of $80K. LENSAR, Inc.'s net income of -$3.7M is higher than Movano, Inc.'s net income of -$4M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.41x versus 12.06x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M MOVEMovano, Inc.12.06x -- $80K -$4M
-
Which has Higher Returns LNSR or NPCE?
NeuroPace, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -12.78%. LENSAR, Inc.'s return on equity of -1013.45% beat NeuroPace, Inc.'s return on equity of -149.8%.
Company Gross Margin Earnings Per Share Invested Capital LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M NPCENeuroPace, Inc.77.39% -$0.11 $89.7M -
What do Analysts Say About LNSR or NPCE?
LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 24.9%. On the other hand NeuroPace, Inc. has an analysts' consensus of $19.25 which suggests that it could grow by 18.9%. Given that LENSAR, Inc. has higher upside potential than NeuroPace, Inc., analysts believe LENSAR, Inc. is more attractive than NeuroPace, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNSRLENSAR, Inc.0 2 0 NPCENeuroPace, Inc.7 0 0 -
Is LNSR or NPCE More Risky?
LENSAR, Inc. has a beta of 0.665, which suggesting that the stock is 33.53% less volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LNSR or NPCE?
LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNSR or NPCE?
LENSAR, Inc. quarterly revenues are $14.3M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. LENSAR, Inc.'s net income of -$3.7M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.41x versus 5.44x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNSRLENSAR, Inc.2.41x -- $14.3M -$3.7M NPCENeuroPace, Inc.5.44x -- $27.4M -$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
